KR20130012688A - 맥강 단백질 이용한 미네랄 결합 펩타이드의 제조방법 - Google Patents
맥강 단백질 이용한 미네랄 결합 펩타이드의 제조방법 Download PDFInfo
- Publication number
- KR20130012688A KR20130012688A KR1020110073987A KR20110073987A KR20130012688A KR 20130012688 A KR20130012688 A KR 20130012688A KR 1020110073987 A KR1020110073987 A KR 1020110073987A KR 20110073987 A KR20110073987 A KR 20110073987A KR 20130012688 A KR20130012688 A KR 20130012688A
- Authority
- KR
- South Korea
- Prior art keywords
- hydrolyzate
- protein
- supernatant
- peptide
- calcium
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 83
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 51
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 37
- 239000011707 mineral Substances 0.000 title claims abstract description 37
- 230000027455 binding Effects 0.000 title claims abstract description 34
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 235000007340 Hordeum vulgare Nutrition 0.000 title claims description 8
- 240000005979 Hordeum vulgare Species 0.000 title claims 2
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 40
- 239000011575 calcium Substances 0.000 claims abstract description 22
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 20
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003513 alkali Substances 0.000 claims abstract description 6
- 235000018102 proteins Nutrition 0.000 claims description 60
- 239000006228 supernatant Substances 0.000 claims description 46
- 102000005701 Calcium-Binding Proteins Human genes 0.000 claims description 38
- 108010045403 Calcium-Binding Proteins Proteins 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 239000012153 distilled water Substances 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 210000003462 vein Anatomy 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000002244 precipitate Substances 0.000 claims description 16
- 238000000108 ultra-filtration Methods 0.000 claims description 16
- 229910000831 Steel Inorganic materials 0.000 claims description 13
- 239000010959 steel Substances 0.000 claims description 13
- 239000008055 phosphate buffer solution Substances 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 238000001641 gel filtration chromatography Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 230000003301 hydrolyzing effect Effects 0.000 claims description 8
- 239000006166 lysate Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 230000000415 inactivating effect Effects 0.000 claims description 7
- 238000004255 ion exchange chromatography Methods 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- 108010046377 Whey Proteins Proteins 0.000 claims description 6
- 102000007544 Whey Proteins Human genes 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 235000021119 whey protein Nutrition 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 208000003098 Ganglion Cysts Diseases 0.000 claims description 3
- 208000005400 Synovial Cyst Diseases 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000005227 gel permeation chromatography Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 abstract description 12
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 12
- 239000003531 protein hydrolysate Substances 0.000 abstract description 9
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 108010009736 Protein Hydrolysates Proteins 0.000 abstract description 5
- 108091005804 Peptidases Proteins 0.000 abstract description 4
- 229910052742 iron Inorganic materials 0.000 abstract description 4
- 238000010306 acid treatment Methods 0.000 abstract description 3
- 239000004365 Protease Substances 0.000 abstract description 2
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 235000014106 fortified food Nutrition 0.000 abstract description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 108090000604 Hydrolases Proteins 0.000 description 8
- 102000004157 Hydrolases Human genes 0.000 description 8
- 235000021251 pulses Nutrition 0.000 description 8
- 241000209219 Hordeum Species 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007065 protein hydrolysis Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000238017 Astacoidea Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 244000045232 Canavalia ensiformis Species 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- KVSCSUPSLAWLTH-UHFFFAOYSA-N OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.P Chemical compound OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.P KVSCSUPSLAWLTH-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 235000010617 Phaseolus lunatus Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Water Supply & Treatment (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
도 2는 맥강단백질을 가수분해하여 펩타이드 제조하는 방법의 순서도이다.
도 3은 도 2에 있어서 맥강단백질 가수분해물의 가수분해 시간에 따른 전기영동 사진(SDS-PAGE)을 나타낸 도이다.
도 4는 도 2에 있어서 맥강단백질 가수분해물의 이온교환 크로마토그램(QAE Sephadex)을 나타낸 도이다.
도 5는 도 4에 있어서 칼슘과 결합성이 높은 분획 F3을 고속액체 크로마토그라피(-NH2 컬럼)에 다시 로딩한 크로마토그램을 나타낸 도이다.
도 6는 도 5에 있어서 칼슘과 결합성이 높은 분획 F31을 겔여과 크로마토그라피(Sephadex G15)에 다시 로딩한 크로마토그램을 나타낸 도이다.
도 7은 도 6의 분획 F311을 겔여과 크로마토그라피(Superdex)에 다시 로딩한 크로마토그램을 나타낸 도이다.
Claims (16)
2) 단계 1)의 단백질에 가수분해효소를 처리하여 가수분해물을 제조하는 단계;
3) 단계 2)의 가수분해물을 한외여과하는 단계; 및
4) 단계 3)의 여과된 가수분해물을 미네랄과 반응시킨 후 미네랄 결합활성을 갖는 펩타이드를 분리하는 단계를 포함하는, 맥강유래 미네랄 결합 펩타이드의 제조방법.
1) 맥강을 노르말 헥산에 1:3(w/w)의 비율로 용해시키는 단계;
2) 단계 1)의 용해물을 교반 후 원심분리한 다음 건조시켜 탈지맥강을 제조하는 단계;
3) 단계 2)의 탈지맥강을 증류수에 1:5(w/w)의 비율로 가수시키는 단계;
4) 단계 3)의 가수분해물을 초음파 균질기로 맥강단백질을 추출하는 단계;
5) 단계 4)의 맥강단백질의 pH를 9.5로 조정하는 단계;
6) 단계 5)의 맥강단백질을 교반 후 원심분리한 다음 상등액을 취하는 단계;
7) 단계 6)의 상등액의 pH를 4.5로 조정하는 단계;
8) 단계 7)의 상등액을 교반 후 원심분리한 침전물을 취하는 단계; 및
9) 단계 8)의 침전물을 증류수로 수세하는 단계를 포함하는 방법에 의해 수행되는 것을 특징으로 하는 맥강유래 미네랄 결합 펩타이드의 제조방법.
1) 단계 2)의 단백질을 인산완충용액에 용해시켜 5%(w/w) 수용액을 제조하는 단계;
2) 단계 1)의 수용액에 플라보자임을 기질 대비 50:1의 비율로 첨가하여 반응시켜 가수분해물을 제조하는 단계;
3) 단계 2)의 가수분해물을 가열시켜 가수분해효소를 불활성화시키는 단계;
4) 단계 3)의 가수분해물을 원심분리한 다음 상등액을 취하는 단계;
5) 단계 4)의 상등액을 한외여과시키는 단계; 및
6) 단계 5)의 여과액을 동결건조시키는 단계를 포함하는 방법에 의해 제조되는 것을 특징으로 하는 맥강유래 미네랄 결합 펩타이드의 제조방법.
2) 단계 1)의 용해물을 교반 후 원심분리한 다음 건조시켜 탈지맥강을 제조하는 단계;
3) 단계 2)의 탈지맥강을 3차 증류수에 1:5(w/w)의 비율로 가수시키는 단계;
4) 단계 3)의 가수분해물을 초음파 균질기로 맥강단백질을 추출하는 단계;
5) 단계 4)의 맥강단백질을 수산화나트륨으로 pH9.5로 조정하는 단계;
6) 단계 5)의 맥강단백질을 교반 후 원심분리한 다음 상등액을 취하는 단계;
7) 단계 6)의 상등액을 염산으로 pH4.5로 조정하는 단계;
8) 단계 7)의 상등액을 교반 후 원심분리한 침전물을 취하는 단계;
9) 단계 8)의 침전물에 증류수를 더하여 pH7.0이 되도록 수세한 맥강단백질을 제조하는 단계;
10) 단계 9)의 맥강단백질을 pH7.0의 인산완충액에 용해시켜 5%(w/w) 수용액을 제조하는 단계;
11) 단계 10)의 수용액에 플라보자임을 기질 대비 50:1의 비율로 첨가하여 반응시켜 가수분해물을 제조하는 단계;
12) 단계 11)의 가수분해물을 90℃에서 5분 가열하여 가수분해효소를 불활성화시키는 단계;
13) 단계 12)의 가수분해물을 원심분리한 후 상등액을 취하는 단계;
14) 단계 13)의 상등액을 분자량 5,000달톤 이하로 한외여과시키는 단계;
15) 단계 14)의 여과된 가수분해물을 동결건조시키는 단계; 및
16) 단계 15)의 여과된 가수분해물을 칼슘과 반응시킨 후 칼슘 결합활성을 갖는 펩타이드를 분리하는 단계를 포함하는, 맥강유래 칼슘결합 펩타이드의 제조방법.
2) 단계 1)의 용해물을 교반 후 원심분리한 다음 건조시켜 탈지맥강을 제조하는 단계;
3) 단계 2)의 탈지맥강을 3차 증류수에 1:5(w/w)의 비율로 가수시키는 단계;
4) 단계 3)의 가수분해물을 초음파 균질기로 맥강단백질을 추출하는 단계;
5) 단계 4)의 맥강단백질을 수산화나트륨으로 pH9.5로 조정하는 단계;
6) 단계 5)의 맥강단백질을 교반 후 원심분리한 다음 상등액을 취하는 단계;
7) 단계 6)의 상등액을 염산으로 pH4.5로 조정하는 단계;
8) 단계 7)의 상등액을 교반 후 원심분리한 침전물을 취하는 단계;
9) 단계 8)의 침전물에 증류수를 더하여 수세한 맥강단백질을 제조하는 단계;
10) 단계 9)의 맥강단백질을 pH7.0의 인산완충액에 용해시켜 5%(w/w) 수용액을 제조하는 단계;
11) 단계 10)의 수용액에 플라보자임을 기질 대비 50:1의 비율로 첨가하여 반응시켜 가수분해물을 제조하는 단계;
12) 단계 11)의 가수분해물을 90℃에서 5분 가열하여 가수분해효소를 불활성화시키는 단계;
13) 단계 12)의 가수분해물을 원심분리한 후 상등액을 취하는 단계;
14) 단계 13)의 상등액을 분자량 5,000달톤 이하로 한외여과시키는 단계;
15) 단계 14)의 여과된 가수분해물을 동결건조시키는 단계;
16) 단계 15)의 여과된 가수분해물을 칼슘과 반응시킨 후 칼슘 결합활성을 갖는 펩타이드를 분리하는 단계; 및
17) 단계 16)의 여과된 가수분해물을 이온교환 크로마토그래피에 로딩하여 10mM 트리스완충용액(Tris-buffer, pH8.0)을 사용하여, 3.3 ml/min의 유속으로 0.5M 소듐클로라이드(NaCl) 함유 완충용액으로 선형구배를 걸어 2시간 45분 내지 2시간 50분 사이에 분획된 분획물을 수득하는 단계를 포함하는 방법으로 제조된, 맥강유래 칼슘결합 펩타이드.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110073987A KR101274268B1 (ko) | 2011-07-26 | 2011-07-26 | 맥강 단백질 이용한 미네랄 결합 펩타이드의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110073987A KR101274268B1 (ko) | 2011-07-26 | 2011-07-26 | 맥강 단백질 이용한 미네랄 결합 펩타이드의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130012688A true KR20130012688A (ko) | 2013-02-05 |
KR101274268B1 KR101274268B1 (ko) | 2013-06-17 |
Family
ID=47893310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110073987A KR101274268B1 (ko) | 2011-07-26 | 2011-07-26 | 맥강 단백질 이용한 미네랄 결합 펩타이드의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101274268B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210076616A (ko) * | 2019-12-16 | 2021-06-24 | 어업회사법인 월드푸드서비시즈 주식회사 | 뼈 성장 효과를 갖는 녹골 유래 칼슘 결합 펩타이드의 제조 방법 |
CN115216507A (zh) * | 2022-02-22 | 2022-10-21 | 西藏阿那达生物医药科技有限责任公司 | 利用双酶解技术分离青稞麸皮多肽的方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102006143B1 (ko) | 2019-05-08 | 2019-08-01 | 주식회사 케이와이바이오 | 체중조절용 단백질 쉐이크 제조방법 |
KR20220054946A (ko) | 2020-10-26 | 2022-05-03 | 주식회사 케이와이바이오 | 마카분말을 이용한 체중조절용 단백질 쉐이크 제조방법 |
-
2011
- 2011-07-26 KR KR1020110073987A patent/KR101274268B1/ko active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210076616A (ko) * | 2019-12-16 | 2021-06-24 | 어업회사법인 월드푸드서비시즈 주식회사 | 뼈 성장 효과를 갖는 녹골 유래 칼슘 결합 펩타이드의 제조 방법 |
CN115216507A (zh) * | 2022-02-22 | 2022-10-21 | 西藏阿那达生物医药科技有限责任公司 | 利用双酶解技术分离青稞麸皮多肽的方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101274268B1 (ko) | 2013-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ko et al. | A novel angiotensin I-converting enzyme (ACE) inhibitory peptide from a marine Chlorella ellipsoidea and its antihypertensive effect in spontaneously hypertensive rats | |
Kuba et al. | Production of angiotensin I-converting enzyme inhibitory peptides from soybean protein with Monascus purpureus acid proteinase | |
CN103992384B (zh) | 一种大黄鱼鱼骨胶原肽及其制备方法和用途 | |
Rawendra et al. | A novel angiotensin converting enzyme inhibitory peptide derived from proteolytic digest of Chinese soft-shelled turtle egg white proteins | |
Toopcham et al. | Characterization and identification of angiotensin I-converting enzyme (ACE) inhibitory peptides derived from tilapia using Virgibacillus halodenitrificans SK1-3-7 proteinases | |
CN103992385A (zh) | 一种大黄鱼鱼鳔抗氧化胶原肽及其制备方法和用途 | |
KR101274268B1 (ko) | 맥강 단백질 이용한 미네랄 결합 펩타이드의 제조방법 | |
EP2309874A1 (en) | Method for preparing a protein hydrolysate | |
Shao et al. | Peptides isolated from black soybean synergistically inhibit the activity of angiotensin converting enzyme (ACE) | |
CN107532157B (zh) | 制备胶原酶的方法以及利用其制备胶原三肽的方法 | |
CN114507702A (zh) | 一种海洋南极磷虾肽及其应用 | |
CN104131055A (zh) | 一种藻红蛋白ace抑制肽的制备方法 | |
CN100526471C (zh) | 一种燕麦蛋白ace抑制肽的制备方法 | |
Weng et al. | Changes of protein in natto (a fermented soybean food) affected by fermenting time | |
CN103194517A (zh) | 一种鹰嘴豆短肽混合物及其制备方法 | |
Reyes-Mendez et al. | Production of calcium-and iron-binding peptides by probiotic strains of Bacillus subtilis, B. clausii and B. coagulans GBI-30 | |
CN111418700A (zh) | 一种金枪鱼肽、其提取方法及作为降压剂的应用 | |
US20220007682A1 (en) | Method for preparing an ipp- and vpp-rich hydrolysate from wheat gluten protein by enzymatic hydrolysis | |
CN1234288C (zh) | 从大豆粉中制备蛋白质水解产物的方法 | |
JP2003250460A (ja) | 乳蛋白質の機能性改質方法 | |
Chen et al. | Production of Angiotensin-I-Converting Enzyme inhibitory peptide from goat milk casein: optimization conditions of complex protease hydrolysate by response surface methodology and purification | |
Salvado et al. | Enzymatic production of bioactive peptides from whey proteins: Their active role and potential health benefits | |
CN113999832A (zh) | 草菇子实体中性蛋白酶、提取纯化方法及其应用 | |
JP4243266B2 (ja) | パエニバチルス属細菌由来のキチナーゼ及びそれをコードする遺伝子 | |
JPH03280835A (ja) | 卵白分解物およびそれを含有する食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20110726 |
|
PA0201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20121120 Patent event code: PE09021S01D |
|
PG1501 | Laying open of application | ||
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20130530 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20130605 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20130607 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20160601 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20160601 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170626 Year of fee payment: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20170626 Start annual number: 5 End annual number: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180530 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20180530 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20200602 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20210317 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20220307 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20230314 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20240314 Start annual number: 12 End annual number: 12 |